H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Oric Pharmaceuticals to $13 from $14 and keeps a Buy rating on the shares post the Q2 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ORIC:
- Oric Pharmaceuticals reports Q2 EPS (50c), consensus (57c)
- ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals Announces $85 Million Private Placement Financing
- Oric Pharmaceuticals announces $85M private placement financing